Health

Beyond Generics: Venkat Nelabhotla Unveils the ‘Develop, Own, Make’ Blueprint for India’s Global Biotech Ascension

12

At the 17th Annual Pharma Leaders Summit, the Vyome CEO lays out a hyper-efficient cross-border model to transform India from a high-volume manufacturer into a high-value intellectual property powerhouse.

At the prestigious 17th Annual Healthcare Leadership Summit & Power Brand Awards—widely recognized as the “Oscars of Indian Healthcare”—Mr. Venkat Nelabhotla, Co-Founder, President, CEO, and Board Member of Vyome Holdings, Inc. and Vyome Therapeutics, Inc., delivered a paradigm-shifting address.

Speaking before an audience of global healthcare executives, clinical innovators, and policymakers, Nelabhotla challenged the conventional narrative of India as merely the “pharmacy of the world” via low-cost generic volumes. Instead, he presented a bold blueprint titled “India’s Next Biotech and Pharma Innovation Leap: Develop, Own, Make, and Commercialize for the World.”

Moving From Volume to Value: The Core Pillars

Nelabhotla’s presentation laid out four foundational drivers engineered to elevate India from a cost-efficient manufacturer into an undisputed global life sciences innovation hub.

  1. DEVELOP: Intellectual Property & Deep Science

The first step requires a shift from reverse-engineering to pioneering first-in-class or best-in-class therapeutics. Nelabhotla highlighted Vyome’s own breakthrough clinical pipeline—specifically VT-1953, a targeted development asset targeting malignant fungating wounds—as an example of solving severe, underserved global medical conditions.

  1. OWN: The “US-India Innovation Corridor”

Nelabhotla argued passionately that true enterprise value resides in owning the molecule. He shared how Vyome pioneered a hyper-capital-efficient R&D model: inventing and securing intellectual property using India’s world-class scientific talent pool, then validating those assets through rigorous US FDA regulatory pathways.

  1. MAKE: Advanced Manufacturing & Bioprocessing

While India already boasts a massive, FDA-compliant manufacturing base, Nelabhotla stressed the urgent need to rapidly institutionalize advanced bioprocessing, complex biologics, and novel drug delivery systems (NDDS). This ensures Indian-made therapeutics meet the uncompromised quality standards of premium global markets.

  1. COMMERCIALIZE: Global Reach and Elite Capital Markets

The final step focuses on orchestrating sophisticated global out-licensing structures and directly accessing elite global capital markets. Nelabhotla underscored this strategy by pointing to Vyome’s own major milestone: transitioning into a debt-free, publicly traded life sciences entity listed on the Nasdaq (Ticker: HIND).

Macro Context & Industry Drivers

The roadmap comes at a critical structural juncture for the Indian healthcare ecosystem, which is characterized by massive developmental strides juxtaposed against persistent funding gaps:

  • The $1.1 Billion Paradox: While major Indian pharma groups are locked in high-stakes legal and regulatory battles globally, nimble players are using cross-border infrastructure to side-step legacy friction.
  • Capital Disparity: Public healthcare spending in India remains historically low at 1% to 2.5% of GDP, creating an environment where deep-tech and life science ventures must aggressively court global institutional investments to fund long-gestation pipelines.
  • The Talent Pivot: With more than 70% of specialized clinical infrastructure concentrated in urban hubs, cross-border biotech models allow Indian researchers to create global impact without succumbing to local infrastructure deficits.

“For India to orchestrate its next quantum leap, the industry must shed its risk-averse posture, embrace bold cross-border capital models, and aggressively pursue the commercialization of homegrown breakthrough science on the global stage.”

Venkat Nelabhotla, Pharma Leaders Summit 2026

The presentation concluded with a resounding call for collaborative disruption. By shifting from high-volume manufacturing to high-value IP ownership, the Indian pharmaceutical industry can successfully move up the value chain to develop, own, and commercialize next-generation cures directly for the global population.

Reflecting on the impact of the presentations, Dr. Satya Brahma, Chairman and Editor-In-Chief of Network 7 Media Group, emphasized the broader mission of the annual gathering and why blueprints like Vyome’s are essential for the industry’s future:  “This is not just a ceremony — it is a platform for visionary leadership. A movement of change, amplifying voices that challenge norms, disrupt complacency, and drive innovation.”— Dr. Satya Brahma, Chairman, Network 7 Media Group  This 17th Annual Pharma Leaders Healthcare Leadership Summit Overview features an in-depth look at the structural challenges and the transformative vision presented by top leaders during the 2026 Mumbai event.

Author

  • Network 7 Media Group is the flagship media of SB Brand Network & is a new age digital media company based in India. In an era where world's biggest personalities & brands are heavily focused on building the image through digital media world,
Tags:

Network 7 Media Group is the flagship media of SB Brand Network & is a new age digital media company based in India. In an era where world's biggest personalities & brands are heavily focused on building the image through digital media world,
Follow Me:

Related Posts

World Renowned Facial Plastic & Oculoplastic Surgeon Dr. Debraj Shome voted as “India’s Most Promising Face in Facial Plastic Surgery Innovations” at ILC POWER BRAND 2015

By

India reports 84 confirmed Coronavirus cases, Govt prepared to address pandemic

By

Death toll due to COVID-19 rises to 1,981; cases climb to 59,662.The total number of cases also include 111 foreign nationals

By

Categories

How to make India future-ready? In an era of ever changing uncertainties.The truth of the matter is India’s monumental blunder years after years in preparing for the future. Have you ever realized that you are remembered only once in five year to vote & the rest of the time, you are treated as an unwanted object.Corruption? Incompetence? Bad planning?. Political corruption is always hard to fathom. Sure, greed typically is the devil paving the road toward graft. But the potential consequences are so severe for persons held in high esteem you would think any sane politician would run from the risk. Indian Affairs led by Satya Brahma, the visionary founder chairman & Editor—In-Chief of the illustrious Network 7 Media Group attempts to make an impact as he makes you the supreme.